To further identify the most critical drug-resistant genes, the aforementioned four genes (PARVA, ATP2B4, SH3BGRL, and GAD1) were added to the OS analysis in the TCGA-PRAD. This evidence concerns the gene PARVA and prostate adenocarcinoma.